Previous close | 216.97 |
Open | 217.16 |
Bid | 0.00 x 800 |
Ask | 0.00 x 1400 |
Day's range | 214.79 - 218.44 |
52-week range | 194.30 - 247.65 |
Volume | |
Avg. volume | 537,541 |
Market cap | 31.655B |
Beta (5Y monthly) | 0.48 |
PE ratio (TTM) | 36.76 |
EPS (TTM) | 5.86 |
Earnings date | 09 Aug 2023 - 14 Aug 2023 |
Forward dividend & yield | 1.76 (0.82%) |
Ex-dividend date | 10 May 2023 |
1y target est | 260.75 |
ZBH vs. RMD: Which Stock Is the Better Value Option?
France’s Jean-Louis Pépin and Germany’s Holger Woehrle presented studies in which treating OSA with CPAP lowered all-cause mortality for PAP vs. non-PAP users with OSAGermany’s Michael Arzt presented new evidence that treating CSA with ASV* caused “a significant and clinically relevant improvement in disease-specific QoL, daytime sleepiness, and quality of sleep” WASHINGTON, May 25, 2023 (GLOBE NEWSWIRE) -- Renowned medical experts at the American Thoracic Society International Conference unveil
Key Insights Given the large stake in the stock by institutions, ResMed's stock price might be vulnerable to their...
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Rider and Haake, both internal promotions, joined ResMed’s executive team on May 1Rider, currently Senior Vice President, Deputy Global General Counsel will succeed retiring Chief Administrative Officer, Global General Counsel, and Secretary David Pendarvis on July 1 SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced the appointment of two new executive team members: Michael Rider, Global General Counsel & Secretary, effective July 1, 2023, and Dawn Haake as
ResMed (RMD) reports a solid third-quarter top line, led by strong device sales growth through steady production and delivery of its cloud-connected flow generator devices to meet high market demand.
ResMed (RMD) delivered earnings and revenue surprises of 7.01% and 7.95%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Year-over-year revenue grows 29%, operating profit up 28%, non-GAAP operating profit up 27%Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 27, 2023 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2023. Third Quarter 2023 HighlightsAll comparisons are to the prior year period Revenue increased by 29% to $1,116.9 million; up 31% on a constant currency bas
SAN DIEGO, April 06, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2023 on Thursday, April 27, 2023, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: •Location:http://investor.resmed.com•Date:
ResMed's (NYSE:RMD) stock up by 7.8% over the past three months. Given that the market rewards strong financials in the...
ResMed to conduct an internal search for a successor general counselAmy Wakeham appointed Chief Communications and Investor Relations Officer, will join ResMed’s executive leadership team SAN DIEGO, March 30, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) announced today that David Pendarvis, chief administrative officer, global general counsel, and secretary, plans to retire, effective June 30, 2023. He will remain in a consulting role with ResMed through December 31, 2023. ResMed will c
U.S. stock markets are going through an unusually volatile period, thanks to the uncertainty posed by the global banking crisis and the Federal Reserve's plan for interest rates. While wild price swings can be nerve-racking for shareholders, choppy markets can also be a great time to pick up shares of top companies at significant discounts to their intrinsic value. Which growth stocks are on watch for a possible entry point?
Investors are optimistic about ResMed's (RMD) Increased demand for its digital health solution.
SAN DIEGO, March 15, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will join a fireside chat at the 2023 KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023, beginning at approximately 3:45 p.m. (Eastern Daylight Time) via webcast. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://investor.resmed.com. The audio-only webcast repla
81% of respondents experience one or more symptoms indicating poor sleep quality, despite 64% saying they’re satisfied with the quantity of their sleepWomen and older generations are less satisfied with the quality and quantity of their sleep compared to the survey’s overall average Annual survey aims to raise awareness for sleep health during National Sleep Awareness Week and World Sleep Day SAN DIEGO, March 13, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) announced today the results f
EYE vs. RMD: Which Stock Is the Better Value Option?
SAN DIEGO, March 07, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will present at the Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023, beginning at approximately 11:20 a.m. (Eastern Daylight Time) via webcast. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://investor.resmed.com. The audio-only webcast replay will be available
Key Insights ResMed's estimated fair value is US$178 based on 2 Stage Free Cash Flow to Equity ResMed is estimated to...
Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), Novo Nordisk A/S (NVO) and Amgen Inc. (AMGN).
ResMed (RMD) continues to see robust demand for its market-leading mask portfolio despite being faced with challenges related to lower new patient setups from a competitor recall.
ResMed ( NYSE:RMD ) Second Quarter 2023 Results Key Financial Results Revenue: US$1.03b (up 16% from 2Q 2022). Net...
ESLOY vs. RMD: Which Stock Is the Better Value Option?
ResMed's (RMD) mask sales growth was strong across the globe, reflecting a post-COVID pandemic awareness about the importance and need for respiratory hygiene and respiratory health.
ResMed (RMD) delivered earnings and revenue surprises of 3.75% and 3.64%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Year-over-year revenue grows 16%, operating profit up 13%, non-GAAP operating profit up 14% Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended December 31, 2022. Second Quarter 2023 HighlightsAll comparisons are to the prior year period Revenue increased by 16% to $1,033.7 million; up 20% on a constant currency